STUDIES ON ANTIBODY-PRODUCING CELLS : III. IDENTIFICATION OF YOUNG PLAQUE-FORMING CELLS BY THYMIDINE-3H LABELING

Mice injected with sheep RBC and then, 4 days later with thymidine-3H, were sacrificed on the day of thymidine-3H injection or 1 or 2 days later. Hemolytic antibody plaque preparations were made of cells from the draining lymph nodes by a thin-plating procedure permitting collection of isolated PFC for electron microscopic examination and radioautography. Of cells obtained on the day of thymidine-3H injections, 65% of the labeled PFC were in the lymphocytic category, in comparison with 13% found previously in the entire population of such cells. The remaining 35% were plasmablasts in early stages of differentiation. Cells obtained 1 day after the thymidine-3H injections showed a shift to a majority of labeled cells in the plasmacytic category. Also, the plasmablasts were substantially more differentiated than those of the previous day, and some mature plasma cells were now seen. The labeled PFC obtained on day 2 gave no indication of further differentiation. Cells of rabbit lymph nodes labeled in vitro with thymidine-3H showed a range of labeled PFC. The majority were in the plasmacytic category, including some mature plasma cells. The data from the experiments with in vivo labeling suggest a direct differentiation from antibody-synthesizing lymphocytes to plasma cells. Further, the in vivo experiments indicated that differentiation from nascent lymphocyte to plasma cell could be essentially completed within 1 day

STUDIES ON ANTIBODY-PRODUCING CELLS : I. ULTRASTRUCTURE OF 19S AND 7S ANTIBODY-PRODUCING CELLS

Antibody-bearing cells of spleen and lymph node of the mouse and rabbit detected by rosette formation with the antigenic red blood cells were collected by micropipet and studied by electron microscopy. More than 300 such cells were examined. In the lymph nodes, rosette-forming cells were all in the lymphocytic and plasmacytic categories. In cells of the mouse spleen, macrophages were also found among the RFC, especially in the later days after immunization. The great majority of the RFC, 70–100%, were of the lymphocytic category. These included small, medium, and large lymphocytes with fine gradations of differentiation, and blast forms with little heterochromatin. The endoplasmic reticulum of these cells occurred in short, very narrow pieces, usually in contact with a mitochondrion. The cells of the plasmacytic category also showed fine gradations from plasmablasts to typical mature plasma cells. Plaque-forming cells of mouse and rabbit were also collected by micropipet. Of 162 such cells, fine gradations were also found throughout the lymphocytic and plasmacytic categories, but in this case the great majority were in the plasmacytic group, and more plasma cells showed amorphous nuclear chromatin. Among antibody-forming cells detected by both reactions, some of the more highly differentiated large lymphocytes contained ER which differed from that in the other large lymphocytes in that the channels were slightly and variably distended, with deposition of some precipitate, and with some tendency to a more nearly parallel orientation of the few channels seen. These were considered transitional cells. Of 10 RFC found in mitosis, all were in the lymphocytic category, in various stages of differentiation, the most advanced of which (in 2 of the 10 cells) was that of the transitional lymphocyte described here. Cells producing plaques facilitated by antisera vs. IgG of the mouse or rabbit (7S) showed the same distribution between cell categories and the same fine gradations as the direct (19S) PFC. Cells producing rosettes which were resistant to lysis in the presence of complement, and were thus presumably producing 7S antibody, showed a distribution similar to that found generally with rosette-forming cells, approximately 80–90% in the lymphocytic category

BK virus large T and VP-1 expression in infected human renal allografts

Objective. We investigated the expression of early and late phase BK virus (BKV) proteins and their interactions with host cell proteins in renal allografts, with ongoing polyomavirus associated nephropathy (PVAN), and correlated this with the nuclear and cell morphology. Methods. Frozen sections from three patients with renal allografts (two biopsies, one explant) with PVAN were analysed by indirect immunofluorescence using BKV specific anti-polyoma large T-antigen and anti-VP-1 antibodies, as well as anti-p53, anti-Ki67, anti-caspase-3, anti-bcl2 and anti-cytokeratin 22 antibodies. Nuclear morphology and size were estimated by DNA Hoechst staining. Results. In infected tubular cells the early and late phases of infection could be distinguished according to expression of large T-antigen or VP-1. The early phase revealed almost normal nuclear proportions, whereas in later phases nuclear size increased about 2 to 3 fold. Expression of large T-antigen was strongly associated with accumulation of p53 in the nucleus, accompanied by the activation of the cell cycle associated cell protein Ki67. In contrast, expression of BKV VP1 correlated only weakly with p53. Virus dependent cell lysis was due to necrosis, since neither caspase 3 nor nuclear nor cytoskeleton changes indicated apoptosis. Conclusion. In our selected patients with PVAN a clear distinction between early and late phases was possible, according to the protein expression patterns of BKV markers. Striking nuclear enlargement is only present in the late phase of infection. In the inflammatory setting of PVAN, BKV dependent effects appear to be mediated by the inhibition of p53, resulting in the activation of the cell cycle. We assume that in PVAN similar BKV mechanisms are operative as in certain in vitro system

BK virus large T and VP-1 expression in infected human renal allografts

Objective. We investigated the expression of early and late phase BK virus (BKV) proteins and their interactions with host cell proteins in renal allografts, with ongoing polyomavirus associated nephropathy (PVAN), and correlated this with the nuclear and cell morphology

Influence of antiretroviral therapy on programmed death-1 (CD279) expression on T cells in lymph nodes of human immunodeficiency virus-infected individuals

Human immunodeficiency virus infection leads to T-cell exhaustion and involution of lymphoid tissue. Recently, the programmed death-1 pathway was found to be crucial for virus-specific T-cell exhaustion during human immunodeficiency virus infection. Programmed death-1 expression was elevated on human immunodeficiency virus-specific peripheral blood CD8+ and CD4+ T cells and correlated with disease severity. During human immunodeficiency infection, lymphoid tissue acts as a major viral reservoir and is an important site for viral replication, but it is also essential for regulatory processes important for immune recovery. We compared programmed death-1 expression in 2 consecutive inguinal lymph nodes of 14 patients, excised before antiretroviral therapy (antiretroviral therapy as of 1997-1999) and 16 to 20 months under antiretroviral therapy. In analogy to lymph nodes of human immunodeficiency virus-negative individuals, in all treated patients, the germinal center area decreased, whereas the number of germinal centers did not significantly change. Programmed death-1 expression was mostly found in germinal centers. The absolute extent of programmed death 1 expression per section was not significantly altered after antiretroviral therapy resulting in a significant-relative increase of programmed death 1 per shrunken germinal center. In colocalization studies, CD45R0+ cells that include helper/inducer T cells strongly expressed programmed death-1 before and during therapy, whereas CD8+ T cells, fewer in numbers, showed a weak expression for programmed death-1. Thus, although antiretroviral therapy seems to reduce the number of programmed death-1-positive CD8+ T lymphocytes within germinal centers, it does not down-regulate programmed death-1 expression on the helper/inducer T-cell subset that may remain exhausted and therefore unable to trigger immune recovery